Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.

Abstract

Sorry, we couldn't extract an abstract for this paper.
DOI: 10.1111/bjh.13516

Topics

  • Presentations referencing similar topics